Fmc-Blythe Desert Dialysis is a medicare approved dialysis facility center in Blythe, California and it has 13 dialysis stations. It is located in Riverside county at 737 W. Hobson Way, Blythe, CA, 92225. You can reach out to the office of Fmc-Blythe Desert Dialysis at (760) 922-4415. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Fmc-Blythe Desert Dialysis has the following ownership type - Profit. It was first certified by medicare in October, 1997. The medicare id for this facility is 052812 and it accepts patients under medicare ESRD program.
| Name | Fmc-Blythe Desert Dialysis |
|---|---|
| Location | 737 W. Hobson Way, Blythe, California |
| No. of Dialysis Stations | 13 |
| Medicare ID | 052812 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| NPI Number | 1932211836 |
| Organization Name | Blythe Desert Dialysis |
| Doing Business As | Bio-medical Applications Of California, Inc. |
| Address | 737 W Hobsonway Blythe, California, 92225 |
| Phone Number | (760) 922-4415 |
| Dialysis patients with Hemoglobin data | 14 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 7 |
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 31 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 292 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Fmc-Blythe Desert Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 32 |
| Hypercalcemia patient months | 301 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 31 |
| Patients with Serumphosphor less than 3.5 mg/dL | 5 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 26 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 36 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 24 |
| Patients with Serumphosphor greater than 7 mg/dL | 10 |
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 33 |
| Patient months included in arterial venous fistula and catheter summaries | 229 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 77 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 5 |
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 23 |
| Hospitalization Rate in facility | 86.8 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 260.8 |
| Hospitalization Rate: Lower Confidence Limit | 31.5 |
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Fmc-Blythe Desert Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.2 (As Expected) |
| SIR: Upper Confidence Limit | 3.97 |
| SIR: Lower Confidence Limit | .2 |
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Fmc-Blythe Desert Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 21 |
| Transfusion Rate in facility | 27.5 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 161 |
| Transfusion Rate: Lower Confidence Limit | 5.8 |
The rate of mortality show you whether patients who were being treated regularly at Fmc-Blythe Desert Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 126 |
| Mortality Rate in facility | 13.5 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 23.6 |
| Mortality Rate: Lower Confidence Limit | 7 |
Fmc-Blythe Desert Dialysis Location: 737 W. Hobson Way, Blythe, California, 92225 Phone: (760) 922-4415 |